Thursday, 28 March 2024
Catalyst Biosciences Inc.
14:18 | 21/2/18
The Ledger Gazette
Catalyst Biosciences logo Media coverage about Catalyst Biosciences (NASDAQ:CBIO) has trended somewhat positive this week, Accern reports.
more»
07:56 | 21/2/18
Business Daily
Catalyst Biosciences, Inc. (NasdaqCM:CBIO) has a current MF Rank of 15979. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price.
more»
02:41 | 21/2/18
Nasdaq Journal
Shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) closed the previous trading session at $31.08, experiencing a change of -6.07% with 546,593 shares trading hands.
more»
01:45 | 21/2/18
Post Analyst
Catalyst Biosciences, Inc. (NASDAQ:CBIO) reached 899.36% versus a 1-year low price of $3.11. The stock was last seen -6.07% lower, reaching at $31.08 on 02/16/2018.
more»
06:03 | 20/2/18
Street Observer
Catalyst Biosciences, Inc. (CBIO) stock price moved with dropping change along with the volume 0.55 million shares in Friday trading session.
more»
05:41 | 16/2/18
GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced ...
more»
21:37 | 13/2/18
Seeking Alpha
Catalyst Biosciences reported positive phase 1/2 data in patients with Hemophiila B using its treatment known as CB 2679d. CB 2679d has the advantage of potentially being the first FDA approved treatment for Hemophilia B patients as a prophylactic ...
more»
10:33 | 13/2/18
GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced ...
more»
01:22 | 10/2/18
GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced top-line data ...
more»
04:22 | 1/2/18
GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced an oral ...
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |